Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

Royalty Pharma (Nasdaq: RPRX) acquired the remaining portion of PTC Therapeutics’ royalty on Roche’s Evrysdi for $240 million upfront plus up to $60 million in sales‑based milestones. Following the deal, Royalty Pharma will own 100% of a tiered 8%–16% royalty on worldwide net sales of Evrysdi.

Evrysdi is an oral SMN2 splicing modifier for spinal muscular atrophy, FDA approved in 2020 and used by >21,000 patients. Evrysdi reported CHF 1.6 billion (~$1.9B) sales in 2024, +18% year‑over‑year at constant FX, and analyst consensus projects CHF 2.3 billion (~$2.9B) by 2030. The increased royalty structure applies starting Q1 2026, based on Q4 2025 product sales.

https://www.stocktitan.net/news/RPRX/royalty-pharma-acquires-remaining-royalty-interest-in-roche-s-jhclr731q0hf.html